Multiple Indications Equals Tens of Billions in Market Size

BALTIMORE, MD--(Marketwired - May 8, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, notes that the market for the Nuvilex, Inc. ( OTCQB : NVLX ) encapsulation delivery system could leap from the single digit billions in annual sales to tens of billions worldwide. Nuvilex is an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.

The Company's live-cell encapsulation drug delivery platform has already demonstrated that it can significantly improve the efficacy and safety results in mid-stage clinical trial studies in patients in advanced stages of pancreatic cancer. Given the ability of the platform to activate pro-drugs and maintain a high degree of safety, management believes that the platform can be used to treat multiple forms of cancer, as evidenced in preclinical studies. Therefore, as the development progresses, it is not inconceivable that the size of the market for platform reaches the tens of billions worldwide.

Since great promise has been demonstrated in its preclinical breast cancer studies, it is possible that trials to treat the $10 billion breast cancer market are next on Nuvilex's list.

Each year, 230,000 women in the U.S. are diagnosed with breast cancer. Interestingly, some of the FDA-approved treatments for breast cancer are being studied now to treat pancreatic cancer. However, to date, some of these treatments have demonstrated lower efficacy and survival rates in pancreatic cancer patients than with breast cancer patients.

Treatments that employ Nuvilex's cell encapsulation technology have demonstrated strong efficacy in mid-stage clinical trials in advanced pancreatic cancer. Therefore, it is possible that the results with breast cancer could ultimately show that the cell encapsulation technology can also be substantially positive, and perhaps even more so, for this indication than they are for pancreatic cancer. 

Finally, since the Nuvilex ( OTCQB : NVLX ) approach serves as an activator for pro-drugs it is possible that it can be used in conjunction with multiple pro-drugs at the tumor site or even as an alternative early stage defense against rapid tumor progression when used in conjunction with other modalities.

To view a summary of Nuvilex reports or download the reports in their entirety, please visit www.goldmanresearch.com

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com .

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com .

About Nuvilex, Inc. ( OTCQB : NVLX ): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com .